Tirzepatide, characterized by its ability to selectively bind and activate receptors for the intestinal hormones GIP and GLP-1, has been tested in numerous clinical studies and is already currently authorized in several countries for the treatment of type 2 diabetes and obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.